Gilead Sciences is a leader in the field of virology treatments. As VP of clinical research for hepatitis, respiratory and emerging viruses at Gilead, Anu Osinusi talked about the pharma company's work in HIV and hepatitis and how her personal background informed her team's work in developing a Covid-19 treatment.
Improving Customer Experience and Conversion in Healthcare & Life Sciences.
At the upcoming INVEST Digital Health conference in Dallas set for September 28, in collaboration with Health Wildcatters, a panel discussion on the future of pharmacy benefit managers will be part of the larger conversation on employee benefits. AJ Loiacono, CapitalRx CEO, shared his perspective on the topic.
A panel discussion from a recent Microsoft summit offered insights on how tech companies are closely collaborating with the pharma industry as they seek to repair and improve manufacturing supply chain issues exposed by the Covid-19 pandemic.
Decentralized clinical trial approaches helped the pharma industry navigate through Covid-19. Now it is becoming increasingly clear that there’s a need for a hybrid approach to decentralized clinical trials that considers the perspectives of patients and the impact to clinical trial sites.
Emergn Principal Consultant Mario Moreira shared insights on how pharma companies can use the principles of Value, Flow and Quality to shorten drug development timelines and deliver better patient outcomes through improved ways of working.
A specialty drug is a class of prescription medications used to treat complex, chronic or rare medical conditions. Although this classification was originally intended to define the treatment of rare, also termed “orphan” diseases, affecting fewer than 200,000 people in the US, more recently, specialty drugs have emerged as the cornerstone of treatment for chronic and complex diseases such as cancer, autoimmune conditions, diabetes, hepatitis C, and HIV/AIDS.
“Most Q&As are happening on Twitter. If you’re not doing social listening you’re losing fresh insights into things like disease states." That was just one of the observations in a new report on how pharma and other life science companies are working with healthcare providers and adapting to improve the patient experience.
“Most Q&As are happening on Twitter. If you’re not doing social listening you’re losing fresh insights into things like disease states." That was just one of the observations in a new report on how pharma and other life science companies are working with healthcare providers and adapting to improve the patient experience.
A look at how healthcare organizations are collaborating with Microsoft to enhance patient engagement, accelerate healthcare innovation, improve clinical and operational insights, and more.
Microsoft seeks to change the way pharma industry companies use technology to better navigate human resource and supply chain challenges.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
By engaging in a dialogue, patients and pharma companies can have a mutually beneficial relationship, Health Union's Jack Barrette said at HLTH’s patient engagement track, hosted by MedCity News. Not only can patients help mold clinical trials, but they can help companies improve their patient education efforts.
Clinical 2021 is US and EU pharma’s leading event for clinical innovators - join 500+ executive attendees from across the globe to meet and learn virtually.
Did you miss the event? Register for the On-Demand Webinar to learn how digital engagement can solve challenges for both patients and the brand and learn other benefits that will improve patient experience and address multiple barriers to medication adherence.
With more readers and greater engagement in our content than ever, we have many products that can help you reach your customer base through our content, ads, podcasts and online events. Contact us to learn more.
Propeller Health and Novartis received the green light from European regulators to package their products together. The move is one step of many to make digital therapeutics easier to prescribe.
